FTSE 100 set for monthly gains; AstraZeneca up after results

By Reuters News

- London's FTSE 100 looked on track to log its first monthly gain in three months, edging up on Friday as AstraZeneca rose, with investors welcoming a budget that was softer than expected on taxes.

The blue-chip FTSE 100 index .FTSE was 0.1% higher at 10,732.58 points by 0941 GMT, adding to the month's gains at 1.3%. The midcap FTSE 250 .FTMC slipped 0.6%.

Here are more details:

  • On the day, AstraZeneca AZN.L rose 3.6%, after the Anglo-Swedish drug-maker announced a restructuring drive that will likely save $1.5 billion and help achieve long-term ambitions, including investing in new drug pipelines

  • The broader pharma sector .FTNMX201030 gained 3%, setting it up for its biggest monthly gain since February

  • Banks .FTNMX301010 weighed most on the index on the day, after NatWest NWG.L lost 7.9% following disappointing third-quarter profit

  • Precious .FTNMX551030 and industrial .FTNMX551020 metal miners lost 3.4% and 1.3%, respectively, tracking declines in gold and copper GOL/ MET/L

  • Oil prices rose about 2% on Friday, set for a fourth monthly gain, with Brent crude futures trading at over $117 a barrel O/R

  • Energy .FTNMX601010 rose 0.2%. BP BP.L was up marginally after it posted a record quarterly net profit

  • Finance Minister John Healey's first budget raised taxes on banks and gambling firms, which were less severe than expected, sparking a rally in the stocks on Wednesday

  • Defence firms also rallied after Healey said that 'reprioritisation' in other departments would fund the government's defence plan. Aerospace and defence firms are among the best performers this week

  • Consumer staples stocks rose on the day, with British American Tobacco BATS.L and Unilever ULVR.L up about 2%

  • Earlier this month, data showed inflation rose more than expected in September, cementing the case for an interest rate hike by the Bank of England in November

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.